Neurotoxicity of Commonly Used Antineoplastic Agents
- 11 July 1974
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 291 (2) , 75-81
- https://doi.org/10.1056/nejm197407112910205
Abstract
THE incidence of neurologic disorders has been steadily increasing in several neoplastic diseases as recent advances in therapy have lengthened patient survival.1 2 3 The neurologic complications of cancer most frequently result from metastasis to the nervous system or compression of neural structures by extraneural tumor. In addition, an interesting group of nonmetastatic neuromuscular disorders has recently been described,4 , 5 and the broad concept of "carcinomatous neuromyopathy" is frequently invoked to explain obscure neurologic symptoms in patients with cancer.6 However, it is also important to realize that neurologic dysfunction may be iatrogenic — i.e., caused by the treatment of cancer. Radiation myelitis and . . .Keywords
This publication has 60 references indexed in Scilit:
- Paraplegia following intrathecal methotrexateThe Journal of Pediatrics, 1973
- IRRADIATION, METHOTREXATE TOXICITY, AND THE TREATMENT OF MENINGEAL LEUKÆMIAThe Lancet, 1973
- Intrathecal toxicity studies with benzyl alcoholToxicology and Applied Pharmacology, 1973
- METHOTREXATE MENINGITISThe Lancet, 1972
- INTRATHECAL METHOTREXATEThe Lancet, 1972
- INTRATHECAL METHOTREXATEThe Lancet, 1971
- INTRATHECAL METHOTREXATEThe Lancet, 1970
- INTRATHECAL METHOTREXATEThe Lancet, 1970
- Brain tumor chemotherapy with intrathecal methotrexateCancer, 1969
- THE NEUROLOGICAL COMPLICATIONS OF NEOPLASMSThe Lancet, 1963